Inclusion Criteria

Patients must have:

• HIV infection.
• Residence in an area endemic for H. capsulatum.
• Absolute CD4 count < 150 cells/mm3.
• No current or past active histoplasmosis.
• No other active fungal infection.
• Life expectancy of at least 1 year.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

• Life-threatening infection or malignancy other than cutaneous Kaposi's sarcoma.
• Inability to take oral medication.

Concurrent Medication:

Excluded:

• Systemically-active antifungals.
• Investigational drugs (expanded access drugs are acceptable).
• Rifampin.
• Rifabutin.
• Terfenadine.
• Astemizole.
• Phenobarbital.
• Phenytoin.
• Carbamazepine.
• H2 blockers.
• Omeprazole.
• Continual antacids.

Patients with the following prior conditions are excluded:

History of intolerance to imidazole or azole compounds.

Prior Medication:

Excluded within 1 month prior to study entry:

• Investigational drugs (expanded access drugs are acceptable).

Excluded within 15 days prior to study entry:

• Rifampin.
• Rifabutin.
• Terfenadine.
• Astemizole.
• Phenobarbital.
• Phenytoin.
• Carbamazepine.